drugset / Trial / NCT04054479

Penehyclidine for PONV Prophylaxis After Strabismus Surgery

NCT04054479

RandomizedParallel-groupDouble-blindPrevention

Summary

Patients scheduled for elective strabismus surgery under general anesthesia in the First Affiliated Hospital of Nanjing Medical University will be included in this study. Patients 1)ASA I or II, 2)aged 3-65 years, 3)scheduled for elective strabismus surgery under general anesthesia, will be included in the study. Patients 1)had prior PONV, 2)severe motion sickness, 3)a history of ophthalmic surgery, 4)had received drugs known to have antiemetic effects, will be excluded from the study. The primary aim is to evaluate the prophylaxis effect of penehyclidine(a novel long acting selective anticholinergic agent developed in China) on postoperative nausea and vomiting after strabismus surgery. Secondary outcomes include the effect of PONV risk factors and surgical technique on PONV rank score, occurance of oculocardiac reflex, time to extubation.

Timeline

Start
2019-07-20
Primary completion
2019-07-22
Completion
2019-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Penehyclidine Small molecule 10 ug/kg

Indications

No indication recorded.